Publisher Full Text
In Vitro Selection of Meropenem Resistance among Ceftazidime-Avibactam-Resistant, Meropenem-Susceptible Klebsiella pneumoniae Isolates with Variant KPC-3 Carbapenemases.Antimicrob Agents Chemother. 2017 05; 61(5)AA
Abstract
Ceftazidime-avibactam resistance is mediated by blaKPC-3 mutations, which restore carbapenem susceptibility. We subjected Klebsiella pneumoniae isolates with different blaKPC-3 mutations (n = 5) or wild-type blaKPC-3 (n = 2) to serial passages with meropenem. The meropenem MIC against each isolate increased. Mutations in the ompK36 porin gene evolved in 5 isolates. Among isolates with D179Y substitutions in KPC-3, blaKPC-3 mutations reverted to wild type, were replaced by new mutations, or were retained. Carbapenem treatment of ceftazidime-avibactam-resistant K. pneumoniae infections may select for carbapenem resistance.
Links
MeSH
Pub Type(s)
Journal Article
Language
eng
PubMed ID
28242667
Citation
Shields, Ryan K., et al. "In Vitro Selection of Meropenem Resistance Among Ceftazidime-Avibactam-Resistant, Meropenem-Susceptible Klebsiella Pneumoniae Isolates With Variant KPC-3 Carbapenemases." Antimicrobial Agents and Chemotherapy, vol. 61, no. 5, 2017.
Shields RK, Nguyen MH, Press EG, et al. In Vitro Selection of Meropenem Resistance among Ceftazidime-Avibactam-Resistant, Meropenem-Susceptible Klebsiella pneumoniae Isolates with Variant KPC-3 Carbapenemases. Antimicrob Agents Chemother. 2017;61(5).
Shields, R. K., Nguyen, M. H., Press, E. G., Chen, L., Kreiswirth, B. N., & Clancy, C. J. (2017). In Vitro Selection of Meropenem Resistance among Ceftazidime-Avibactam-Resistant, Meropenem-Susceptible Klebsiella pneumoniae Isolates with Variant KPC-3 Carbapenemases. Antimicrobial Agents and Chemotherapy, 61(5). https://doi.org/10.1128/AAC.00079-17
Shields RK, et al. In Vitro Selection of Meropenem Resistance Among Ceftazidime-Avibactam-Resistant, Meropenem-Susceptible Klebsiella Pneumoniae Isolates With Variant KPC-3 Carbapenemases. Antimicrob Agents Chemother. 2017;61(5) PubMed PMID: 28242667.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - In Vitro Selection of Meropenem Resistance among Ceftazidime-Avibactam-Resistant, Meropenem-Susceptible Klebsiella pneumoniae Isolates with Variant KPC-3 Carbapenemases.
AU - Shields,Ryan K,
AU - Nguyen,M Hong,
AU - Press,Ellen G,
AU - Chen,Liang,
AU - Kreiswirth,Barry N,
AU - Clancy,Cornelius J,
Y1 - 2017/04/24/
PY - 2017/01/12/received
PY - 2017/02/19/accepted
PY - 2017/3/1/pubmed
PY - 2017/12/12/medline
PY - 2017/3/1/entrez
KW - KPC mutations
KW - Klebsiella pneumoniae carbapenemase
KW - carbapenem-resistant Enterobacteriaceae
KW - ceftazidime-avibactam resistance
KW - sequence type 258 Klebsiella pneumoniae
JF - Antimicrobial agents and chemotherapy
JO - Antimicrob Agents Chemother
VL - 61
IS - 5
N2 - Ceftazidime-avibactam resistance is mediated by blaKPC-3 mutations, which restore carbapenem susceptibility. We subjected Klebsiella pneumoniae isolates with different blaKPC-3 mutations (n = 5) or wild-type blaKPC-3 (n = 2) to serial passages with meropenem. The meropenem MIC against each isolate increased. Mutations in the ompK36 porin gene evolved in 5 isolates. Among isolates with D179Y substitutions in KPC-3, blaKPC-3 mutations reverted to wild type, were replaced by new mutations, or were retained. Carbapenem treatment of ceftazidime-avibactam-resistant K. pneumoniae infections may select for carbapenem resistance.
SN - 1098-6596
UR - https://www.unboundmedicine.com/medline/citation/28242667/In_Vitro_Selection_of_Meropenem_Resistance_among_Ceftazidime_Avibactam_Resistant_Meropenem_Susceptible_Klebsiella_pneumoniae_Isolates_with_Variant_KPC_3_Carbapenemases_
L2 - http://aac.asm.org/cgi/pmidlookup?view=long&pmid=28242667
DB - PRIME
DP - Unbound Medicine
ER -